Amgen's (AMGN) Kyprolis Granted Priority Review by U.S. FDA
Tweet Send to a Friend
Amgen (NASDAQ: AMGN) announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE